The stock of XBiotech Inc. (NASDAQ:XBIT) is a huge mover today! The stock decreased 2.75% or $0.32 during the last trading session, reaching $11.49. About 290,397 shares traded or 87.70% up from the average. XBiotech Inc. (NASDAQ:XBIT) has risen 58.92% since November 29, 2018 and is uptrending. It has outperformed by 58.92% the S&P500.
The move comes after 5 months positive chart setup for the $472.09M company. It was reported on Nov, 29 by Barchart.com. We have $11.83 PT which if reached, will make NASDAQ:XBIT worth $14.16M more.
More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Globenewswire.com which released: “XBiotech Highlights Third Quarter Developments for 2018 Nasdaq:XBIT – GlobeNewswire” on October 31, 2018, also Globenewswire.com with their article: “XBiotech Added to Russell 3000® Index Nasdaq:XBIT – GlobeNewswire” published on June 11, 2019, Globenewswire.com published: “XBiotech Adds Dr. Peter Libby, Renowned Cardiologist and Research Pioneer in Inflammation and Cardiovascular Disease, to its Corporate Board – GlobeNewswire” on July 10, 2019. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Globenewswire.com and their article: “XBiotech Announces First Patient Enrolled in Randomized Multi-Center Clinical Study Evaluating Bermekimab Therapy in Patients with Hidradenitis Suppurativa – GlobeNewswire” published on October 23, 2019 as well as Globenewswire.com‘s news article titled: “XBiotech Announces Successful Completion of GMP Audit – GlobeNewswire” with publication date: December 03, 2018.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $472.09 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.